This is a website for healthcare professionals.
AVISE Rheumatology Testing is the Most Accurate Solution for Actionable Results.
Backed by science and evidence, AVISE Lupus powered by CB-CAPs, has been shown to increase physician confidence in both ruling in and ruling out SLE, leading to treatment initiation in positive patients and higher patient-reported outcomes.
Actionable results where conventional testing is negative
Increased odds for SLE diagnosis when AVISE Lupus is positive and anti-dsDNA is negative.
Reduction in tests used
Costs for diagnostic tests decrease twice as much compared to patients tested with General Reference Lab tests in the year following AVISE or General Reference Lab testing.
Earlier initiation of therapy that mitigates disease progression
Increased odds of initiation when AVISE is positive and anti-dsDNA negative.
Reduction in healthcare costs
$2,000 in savings per eligible patient.
Manage every step of your patient’s lupus journey with the AVISE® complete portfolio of tests
View Test Portfolio
AVISE Diagnose
Diagnose the right autoimmune disease with confidence
AVISE Prognose
Prognose which organs may be under attack
AVISE Monitor
Monitor disease progression with unique serological markers
When you need accuracy, you need AVISE testing
AVISE
Testing
Testing
General Reference
Lab Testing
Lab Testing
Exclusively available through AVISE, our proprietary Cell-Bound Complement Activation Products (CB-CAPs) provide unprecedented insights and 22% greater sensitivity over traditional laboratory testing.
The AVISE Lupus algorithm integrates CB-CAPs together with autoantibody levels to provide a balanced diagnostic result with 80% sensitivity and 86% specificity for the diagnosis of SLE.
Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med. 2014 Oct 1;1(1):e000056. doi: 10.1136/lupus-2014-000056. PMID: 25396070; PMCID: PMC4225732.
Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.
Wallace DJ, Silverman SL, Conklin J, Barken D, Dervieux T. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Sci Med. 2016 Feb 1;3(1):e000127. doi: 10.1136/lupus-2015-000127. PMID: 26870391; PMCID: PMC4746498.
Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.
Wallace DJ, Silverman SL, Conklin J, Barken D, Dervieux T. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Sci Med. 2016 Feb 1;3(1):e000127. doi: 10.1136/lupus-2015-000127. PMID: 26870391; PMCID: PMC4746498.
Dervieux T, Conklin J, Ligayon JA, Wolover L, O'Malley T, Alexander RV, Weinstein A, Ibarra CA. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. J Immunol Methods. 2017 Jul;446:54-59. doi: 10.1016/j.jim.2017.04.001. Epub 2017 Apr 5. PMID: 28389175.
The only autoimmune testing company with four peer-reviewed clinical utility trials demonstrating a consistent finding that the AVISE CTD test yields actionable information that informs diagnostic and treatment decisions.
Alexander RV, Rey DS, Conklin J, Domingues V, Ahmed M, Qureshi J, Weinstein A. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. . Lupus Sci Med. 2021 Jul;8(1):e000528. doi: 10.1136/lupus-2021-000528. PMID: 34253650; PMCID: PMC8276296.
Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. . Lupus Sci Med. 2020 Mar 18;7(1):e000345. doi: 10.1136/lupus-2019-000345. PMID: 32231785; PMCID: PMC7101049.
Wallace DJ, Alexander RV, O'Malley T, Khosroshahi A, Hojjati M, Loupasakis K, Alper J, Sherrer Y, Fondal M, Kataria R, Powell T, Ibarra C, Narain S, Massarotti E, Weinstein A, Dervieux T. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Sci Med. 2019 Sep 19;6(1):e000349. doi: 10.1136/lupus-2019-000349. PMID: 31592328; PMCID: PMC6762037.
Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol J. 2016 Oct 31;10:71-80. doi: 10.2174/1874312901610010071. PMID: 27867431; PMCID: PMC5101629.
Alexander RV, Rey DS, Conklin J, Domingues V, Ahmed M, Qureshi J, Weinstein A. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. . Lupus Sci Med. 2021 Jul;8(1):e000528. doi: 10.1136/lupus-2021-000528. PMID: 34253650; PMCID: PMC8276296.
Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. . Lupus Sci Med. 2020 Mar 18;7(1):e000345. doi: 10.1136/lupus-2019-000345. PMID: 32231785; PMCID: PMC7101049.
Wallace DJ, Alexander RV, O'Malley T, Khosroshahi A, Hojjati M, Loupasakis K, Alper J, Sherrer Y, Fondal M, Kataria R, Powell T, Ibarra C, Narain S, Massarotti E, Weinstein A, Dervieux T. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Sci Med. 2019 Sep 19;6(1):e000349. doi: 10.1136/lupus-2019-000349. PMID: 31592328; PMCID: PMC6762037.
Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol J. 2016 Oct 31;10:71-80. doi: 10.2174/1874312901610010071. PMID: 27867431; PMCID: PMC5101629.
AVISE testing is performed exclusively in Exagen’s centralized state-of-the-art rheumatology laboratory giving you consistently accurate results.
Take control over your patient’s autoimmune disease.
Request a Consultation
Would you like to learn more about AVISE testing or request a technical consultation about a test report?
Contact us using the form below and a representative will contact you shortly.
